971 related articles for article (PubMed ID: 24530815)
21. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
[TBL] [Abstract][Full Text] [Related]
23. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.
Previs R; Leath CA; Coleman RL; Herzog TJ; Krivak TC; Brower SL; Tian C; Secord AA
Gynecol Oncol; 2015 Aug; 138(2):267-71. PubMed ID: 26037898
[TBL] [Abstract][Full Text] [Related]
25. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
26. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
[TBL] [Abstract][Full Text] [Related]
27. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience.
Bamias A; Karadimou A; Soupos N; Sotiropoulou M; Zagouri F; Haidopoulos D; Thomakos N; Rodolakis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2011 Oct; 123(1):37-42. PubMed ID: 21764430
[TBL] [Abstract][Full Text] [Related]
29. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
[TBL] [Abstract][Full Text] [Related]
30. Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
van Vliet MM; Schreuder HW; Pasker-de Jong PC; Duk MJ
Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():72-8. PubMed ID: 26177496
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Hainsworth JD; Thompson DS; Bismayer JA; Gian VG; Merritt WM; Whorf RC; Finney LH; Dudley BS
Cancer Med; 2015 May; 4(5):673-81. PubMed ID: 25556916
[TBL] [Abstract][Full Text] [Related]
32. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
34. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
35. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Coleman RL; Spirtos NM; Enserro D; Herzog TJ; Sabbatini P; Armstrong DK; Kim JW; Park SY; Kim BG; Nam JH; Fujiwara K; Walker JL; Casey AC; Alvarez Secord A; Rubin S; Chan JK; DiSilvestro P; Davidson SA; Cohn DE; Tewari KS; Basen-Engquist K; Huang HQ; Brady MF; Mannel RS
N Engl J Med; 2019 Nov; 381(20):1929-1939. PubMed ID: 31722153
[TBL] [Abstract][Full Text] [Related]
36. Dose-dense approaches to ovarian cancer treatment.
Katsumata N
Curr Treat Options Oncol; 2015 May; 16(5):21. PubMed ID: 25859831
[TBL] [Abstract][Full Text] [Related]
37. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
[TBL] [Abstract][Full Text] [Related]
39. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
[TBL] [Abstract][Full Text] [Related]
40. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
